Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol accounting

Executive Summary

SEC opens a formal inquiry into Bristol-Myers Squibb's accounting practices related to wholesaler inventory levels (1"The Pink Sheet" Aug. 19, In Brief)...

You may also be interested in...

Bristol SEC inquiry

SEC wholesaler inventory inquiry "may become a more formal investigation," Bristol-Myers Squibb says in 10-Q filed with the Securities & Exchange Commission Aug. 14. "One possible outcome could be a restatement of our results reflecting the previously disclosed wholesaler inventory buildup." Bristol has already restated the estimated impact from excess inventories three times; the most recent estimate implies a revenue impact of nearly $5 bil. (1"The Pink Sheet" July 29, In Brief). "We believe our accounting treatment for the wholesaler inventory buildup was appropriate and, accordingly, believe that this outcome is unlikely"...

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Covid-19 Scam Complaints Double In A Week, But FTC Enforcement Considers 'Good Faith' Factor

FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts